National Institutes of Health, a Component of the US Dept. of Health & Human Services

Ulrich Baxa

Michael Gordon Joyce

Yongping Yang

Ivelin Georgiev

Aliaksandr Druz

Peter D Kwong

Barney S Graham

Yaroslav Tsybovsky

Joseph Van Galen

John R Mascola

Baoshan Zhang

Guillaume Stewart-Jones

Marie Pancera

Cheng Cheng

Wing-Pui Kong

Man Chen

Li Ou

Mallika Sastry

Cinque Soto

Paul Thomas

Emily Rundlet

Masaru Kanekiyo

Jeffrey C Boyington

John Mascola

Syed M Moin

Tongqing Zhou

Gwo-Yu Chuang

Jason Gorman

Rebecca M Lynch

Priyamvada Acharya

Rita Chen

Rebecca Lynch

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Substitutions-modified prefusion RSV F proteins and their use

Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Growing community of inventors

Frederick, MD, United States of America

Ulrich Baxa